Second, this study did not explore Mex3a promoter methylation in the context of other pathogens or liver cancer, such as HCV infection, alcohol-related liver disease, or non-alcoholic fatty liver disease. Here, MEX3A is linked to metabolic dysfunction-associated steatotic liver disease.